Literature DB >> 26550371

Distribution of monocyte chemoattractant protein-1 (MCP-1 A-2518G) and chemokine receptor (CCR2-V64Ι) gene variants in hyperbilirubinemic newborns.

Fatma Narter1, Elif Sinem Bireller2, Can Engin2, Tolga Catmakas2, Fehmi Narter3, Arzu Ergen2, Bedia Cakmakoglu2.   

Abstract

Hyperbilirubinemia is one of the most crucial syndromes, which is characterized by high levels of bilirubin, especially when it occurs in newborns. Bilirubin has cytoprotective properties with an antioxidant function and plays several major roles in the inflammation process with its members such as chemokines. The monocyte chemoattractant protein-1 (MCP-1) is a member of the C-C chemokine family and it has been associated with the inflammatory process. There are no data on the chemokine and its receptor genotypes in hyperbilirubinemic newborns to show their distribution. The aim of this study is to investigate the genotypic relationship of MCP-1 and its receptor CCR2-V64Ι with hyperbilirubinemia in Turkish newborns. A total of 85 newborns were included in the study: 20 infants with hyperbilirubinemia (hyperbilirubinemic group) and 65 infants without hyperbilirubinemia (non-hyperbilirubinemic group). Genotyping of MCP-1 A-2518G and CCR2-V64Ι gene polymorphisms were detected by PCR-RFLP, respectively. MCP-1 GG genotype in patients was higher than the controls and this genotype had 2.69 times higher risk for hyperbilirubinemic neonates (P: 0.20). The frequency of MCP-1 A-2518G G+ genotype in patients was higher than the controls (55.0% and 38.5%, respectively). The results of our preliminary study suggest that MCP-1 G+ genotype has the ability to increase the hyperbilirubinemia risk of newborns. These results should be focused on to research on a larger scale to confirm the findings.

Entities:  

Keywords:  CCR2; MCP-1 and newborn; hyperbilirubinemia

Year:  2015        PMID: 26550371      PMCID: PMC4613056     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

Review 1.  The MCP/eotaxin subfamily of CC chemokines.

Authors:  E Van Coillie; J Van Damme; G Opdenakker
Journal:  Cytokine Growth Factor Rev       Date:  1999-03       Impact factor: 7.638

Review 2.  Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases.

Authors:  Zdenka Navratilova
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2006-11       Impact factor: 1.245

3.  MCP-1 and CCR2 gene variants in oral squamous cell carcinoma.

Authors:  K Bektas-Kayhan; M Unur; Z Boy-Metin; B Cakmakoglu
Journal:  Oral Dis       Date:  2011-08-24       Impact factor: 3.511

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  CCR2-64I is a risk factor for development of bladder cancer.

Authors:  K F Narter; B Agachan; S Sozen; Z B Cincin; T Isbir
Journal:  Genet Mol Res       Date:  2010-04-13

6.  Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women.

Authors:  Rukset Attar; Bedia Agachan; Sibel Bulgurcuoglu Kuran; Canan Cacina; Seyma Sozen; Leman Melis Yurdum; Erkut Attar; Turgay Isbir
Journal:  In Vivo       Date:  2010 Mar-Apr       Impact factor: 2.155

7.  Risk factors for neurotoxicity in newborns with severe neonatal hyperbilirubinemia.

Authors:  Rasha Gamaleldin; Iman Iskander; Iman Seoud; Hanan Aboraya; Aleksandr Aravkin; Paul D Sampson; Richard P Wennberg
Journal:  Pediatrics       Date:  2011-09-12       Impact factor: 7.124

Review 8.  Hyperbilirubinemia in the newborn.

Authors:  Bryon J Lauer; Nancy D Spector
Journal:  Pediatr Rev       Date:  2011-08

9.  Bilirubin inhibits bile acid induced apoptosis in rat hepatocytes.

Authors:  A Granato; G Gores; M T Vilei; R Tolando; C Ferraresso; M Muraca
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 10.  MCP-1/CCL2 as a therapeutic target in myocardial infarction and ischemic cardiomyopathy.

Authors:  Ying Xia; Nikolaos G Frangogiannis
Journal:  Inflamm Allergy Drug Targets       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.